63725-51-9

Basic information

• Product Name: 6-chloro-1H-pyrazolo[3,4-b]pyridine
• Synonyms: 6-chloro-1H-pyrazolo[3,4-b]pyridine;6-Chloro-1H-pyrazolo[3,4-...;7-Aza-6-chloro-1H-indazole;1H-Pyrazolo[3,4-b]pyridine, 6-chloro-;6-chloro-1H-pyrazolo[3
• CAS NO: 63725-51-9
• Molecular Formula: C₆H₄ClN₃
• Molecular Weight: 153.57
• Product Categories: Heterocycle-Pyridine series
• Mol File: 63725-51-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 262℃
• Flash Point: 113℃
• Appearance: /
• Density: 1.61
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.72
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 5.20±0.40(Predicted)
• CAS DataBase Reference: 6-chloro-1H-pyrazolo[3,4-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-1H-pyrazolo[3,4-b]pyridine(63725-51-9)
• EPA Substance Registry System: 6-chloro-1H-pyrazolo[3,4-b]pyridine(63725-51-9)

Safety Data

• Hazardous Substances Data: 63725-51-9(Hazardous Substances Data)

Usage

General Description

6-Chloro-1H-pyrazolo[3,4-b]pyridine is a chemical compound with the molecular formula C7H5ClN4. It is a heterocyclic compound and belongs to the class of pyridine and pyrazole derivatives. 6-Chloro-1H-pyrazolo[3,4-b]pyridine is of interest in pharmaceutical and agrochemical research due to its potential as a building block in the synthesis of various bioactive compounds. It has also been studied for its potential pharmacological and biological activities, including its potential as an anti-cancer and anti-inflammatory agent. 6-Chloro-1H-pyrazolo[3,4-b]pyridine is used as a research tool in the development of new drugs and may have future applications in the pharmaceutical industry.

InChI:InChI=1/C6H4ClN3/c7-5-2-1-4-3-8-10-6(4)9-5/h1-3H,(H,8,9,10)

Upstream product

• 2402-78-0 2,6-dichloropyridine 
• 55304-73-9 2,6-dichloro-pyridine-3-carbaldehyde 
• 271-73-8 1H-Pyrazolo[3,4-b]pyridine 
• 924909-11-5 1H-pyrazolo[3,4-b]pyridine 7-oxide 
• 1093880-37-5 6-chloro-2-fluoropyridine-3-carboxaldehyde 

Downstream Products

• 1357946-70-3 3-bromo-6-chloro-1H-pyrazolo[3,4-b]pyridine 
• 1259223-95-4 6-chloro-3-iodo-1H-pyrazolo[3,4-b]pyridine 
• 1614234-27-3 6-(3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine 
• 1614233-32-7 6-(2,6-difluoro-3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine 

Relevant articles and documents

Development of a Scalable Method for Manufacturing the Central Core of CD73 Inhibitor AB680

AB680 is a highly potent CD73 small molecule inhibitor discovered and developed by Arcus Biosciences, currently in clinical trials for the treatment of pancreatic cancer. Here, we report the development of a scalable and practical method for the manufacturing of the azaindazole central core. This synthesis features an N-oxide formation followed by an α-chlorination with POCl3 leading to the formation of 4,6-dichloro-1H-pyrazolo[3,4-b]pyridine 1 in high yield and 99.5% UV purity. This method was successfully performed on multikilogram scale to support the synthesis of AB680.

Heterocyclic compound used as MNK inhibitor

The invention relates to a heterocyclic compound, a pharmaceutical composition containing the heterocyclic compound, a preparation method thereof, and application thereof used as a mitogen activated protein kinase interacting kinase 1 and 2-MNK1/MNK2 inhibitor. The inhibitor is the heterocyclic compound as shown in the formula (I), or its pharmaceutically acceptable salt, prodrug, solvent compound, polycrystal, isomer, stable isotope derivative or a pharmaceutical composition containing the heterocyclic compound. The compound of the invention can be used for treating or preventing MNK-mediatedrelated diseases, such as cancers.

INHIBITORS OF BRUTON'S TYROSINE KINASE

Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.